Compare MLYS & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | USNA |
|---|---|---|
| Founded | 2019 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 371.5M |
| IPO Year | 2023 | 1996 |
| Metric | MLYS | USNA |
|---|---|---|
| Price | $36.17 | $19.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $47.33 | $36.00 |
| AVG Volume (30 Days) | ★ 1.5M | 141.6K |
| Earning Date | 02-11-2026 | 10-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $912,670,000.00 |
| Revenue This Year | N/A | $9.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.13 |
| Revenue Growth | N/A | ★ 5.88 |
| 52 Week Low | $8.24 | $18.48 |
| 52 Week High | $47.65 | $38.32 |
| Indicator | MLYS | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 42.81 |
| Support Level | $36.50 | $19.44 |
| Resistance Level | $37.75 | $19.98 |
| Average True Range (ATR) | 1.57 | 0.51 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 28.02 | 7.00 |
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.